Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond (Q64122405)

25 June 2019

2 October 2019

5 November 2020

25 January 2021

3 May 2021

Sorafenib in advanced hepatocellular carcinoma

25 July 2022

cites work

1 reference

12 December 2020

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

1 reference

12 December 2020

Effect of vitamin K2 on the recurrence of hepatocellular carcinoma

1 reference

12 December 2020

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

1 reference

12 December 2020

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

1 reference

12 December 2020

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

1 reference

12 December 2020

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

1 reference

12 December 2020

Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study

1 reference

12 December 2020

Control of the immune response by pro-angiogenic factors

1 reference

12 December 2020

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

1 reference

12 December 2020

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

1 reference

12 December 2020

Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.

1 reference

12 December 2020

Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update

1 reference

12 December 2020

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

1 reference

12 December 2020

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

1 reference

12 December 2020

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

1 reference

12 December 2020

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

1 reference

12 December 2020

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

1 reference

12 December 2020

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial

1 reference

12 December 2020

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis

1 reference

12 December 2020

Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma

1 reference

12 December 2020

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

12 December 2020

Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update

1 reference

12 December 2020

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib

1 reference

12 December 2020

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

1 reference

12 December 2020

Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials

1 reference

12 December 2020

Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives

1 reference

12 December 2020

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

1 reference

12 December 2020

S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial

1 reference

12 December 2020

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses

1 reference

12 December 2020

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

1 reference

12 December 2020

A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.

1 reference

12 December 2020

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

1 reference

12 December 2020

Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

1 reference

12 December 2020

Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions

1 reference

12 December 2020

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

1 reference

12 December 2020

Lenvatinib in Advanced Hepatocellular Carcinoma

1 reference

12 December 2020

Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials

1 reference

12 December 2020

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

1 reference

12 December 2020

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.

1 reference

12 December 2020

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

1 reference

12 December 2020

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

1 reference

12 December 2020

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

1 reference

12 December 2020

Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial

1 reference

12 December 2020

ADI-PEG 20 Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma.

1 reference

12 December 2020

Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma

1 reference

12 December 2020

Combination Cancer Immunotherapy in Hepatocellular Carcinoma

1 reference

12 December 2020

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

1 reference

12 December 2020

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

1 reference

12 December 2020

Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma

1 reference

12 December 2020

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

1 reference

12 December 2020

Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma

1 reference

12 December 2020

Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial

1 reference

12 December 2020

Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)

1 reference

12 December 2020

Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma

1 reference

12 December 2020

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

12 December 2020